FDA approves Supernus epilepsy drug
ROCKVILLE, Md. — The Food and Drug Administration has approved a new epilepsy drug made by Supernus Pharmaceuticals, the company said Monday.
Supernus announced the approval of Trokendi XR, a once-daily, extended-release formulation of the drug topiramate. As part of the approval, the FDA granted Supernus a waiver for some of the requirements for studies of the drug in children and a deferral for submission of other post-marketing data due in 2019, followed by clinical assessments in 2025.
"We are very excited about the approval of Trokendi XR and its upcoming launch," Supernus president, director and CEO Jack Khattar said. "This is excellent news for Supernus, its shareholders and patients with epilepsy. We remain committed to the epilepsy community and very much look forward to now having two products, Trokendi XR and Oxtellar XR, available to patients."
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.
DrFuhrman.com discontinues supplement cancer claims following National Advertising Division challenge
NEW YORK — DrFuhrman.com on Monday informed the National Advertising Division that the company has discontinued certain advertising claims — including “anti-cancer” and cancer treatment claims — made for the company’s Immunotect dietary supplement.
The claims at issue were challenged by the Council for Responsible Nutrition.
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.
As part of its routine monitoring program, and in conjunction with NAD’s initiative with CRN to expand the review of advertising claims made for supplements, NAD requested that DrFuhrman provide substantiation for more than a dozen claims.
Bosley Professional Strength reaffirms commitment to healthier hair, develops new products
PLACENTIA, Calif. — Hair restoration brand Bosley is helping to spread awareness of hair loss during National Hair Loss Awareness Month in August and offer treatment options for those battling fine and thinning hair with two new products — BosRenew Volumizing Dry Shampoo and BosRenew Scalp Micro-Dermabrasion.
According to the manufacturer, roughly 50 million men and 30 million women in the United States are affected by hair loss. Given these staggering numbers, the Academy of Dermatology has designated August as National Hair Loss Awareness Month to help educate the public on signs, symptoms and treatment options.
Beyond absorbing dirt, excess oil and product build-up, the BosRenew Volumizing Dry Shampoo also may help stimulate the metabolic function of cells, serving to create voluminous, ultra-manageable and silky-soft hair. The multitasking formula even provides UV protection to defend hair against photo-aging.
Known as a "facial for the scalp," the BosRenew Scalp Micro-Dermabrasion is a treatment that provides the restorative exfoliating benefits of a facial, but for your scalp. Offered exclusively in salons, it addresses hair and scalp aging at the cellular level, exfoliating dead skin cells and unclogging the follicles to allow hair to grow in a healthy environment. Improving follicle health is key to helping diminish hair loss.
Committed to educating the public on hair loss and delivering viable solutions, Bosley Professional Strength goes beyond its line of products to provide training and seminars for stylists so they can offer guidance to clients.
Bosley Professional Strength is available at Ulta Beauty, professional beauty salons and barber shops nationwide.